Ascendant Resources Inc (TSE:ASND) Director Mark Peter Brennan bought 287,000 shares of the firm’s stock in a transaction on Wednesday, April 19th. The stock was bought at an average price of C$0.63 per share, with a total value of C$180,810.00.

WARNING: This article was originally published by Financial Market News and is owned by of Financial Market News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at

About Ascendant Resources

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Receive News & Ratings for Ascendant Resources Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendant Resources Inc and related companies with's FREE daily email newsletter.